Paula Proszek

4.0k total citations
17 papers, 120 citations indexed

About

Paula Proszek is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Paula Proszek has authored 17 papers receiving a total of 120 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Paula Proszek's work include Multiple Myeloma Research and Treatments (6 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer Treatment and Pharmacology (4 papers). Paula Proszek is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), Cancer Genomics and Diagnostics (6 papers) and Cancer Treatment and Pharmacology (4 papers). Paula Proszek collaborates with scholars based in United Kingdom, United States and Netherlands. Paula Proszek's co-authors include Dil Begum, Eileen M. Boyle, Nasrin Dahir, Fiona M. Ross, Gareth J. Morgan, Martin Kaiser, Christopher P. Wardell, Brian A. Walker, Mark T. Drayson and Faith E. Davies and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Paula Proszek

13 papers receiving 120 citations

Peers

Paula Proszek
Sumito Shingaki Japan
L. Qiu China
Omar Saavedra Spain
Sandra Salazar United States
Sivahari Prasad Gorantla Germany
Yusuke Isshiki Japan
Yih-Chih Chan Australia
Gabriela Borsaru Romania
Ikuko Omori Japan
Max F. Levine United States
Sumito Shingaki Japan
Paula Proszek
Citations per year, relative to Paula Proszek Paula Proszek (= 1×) peers Sumito Shingaki

Countries citing papers authored by Paula Proszek

Since Specialization
Citations

This map shows the geographic impact of Paula Proszek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paula Proszek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paula Proszek more than expected).

Fields of papers citing papers by Paula Proszek

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paula Proszek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paula Proszek. The network helps show where Paula Proszek may publish in the future.

Co-authorship network of co-authors of Paula Proszek

This figure shows the co-authorship network connecting the top 25 collaborators of Paula Proszek. A scholar is included among the top collaborators of Paula Proszek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paula Proszek. Paula Proszek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Cairns, David A., Charlotte Pawlyn, Eugene B. Ferris, et al.. (2025). Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling. Blood. 146(22). 2670–2680.
2.
Levink, Iris J. M., Charlotte Fribbens, Paula Proszek, et al.. (2025). Clinical and Molecular Profiling of Colorectal Cancer: A Comprehensive Cohort Study of BRAF-Mutated Cases from a Tertiary Centre. Current Oncology. 32(9). 507–507.
3.
Chisholm, Julia, Joanna Selfe, Rita Alaggio, et al.. (2024). Clinicopathological Analysis of a European Cohort of MYOD1 Mutant Rhabdomyosarcomas in Children and Young Adults. Pediatric Blood & Cancer. 72(1). e31428–e31428. 3 indexed citations
4.
Proszek, Paula, Paul Carter, Andrew Feber, et al.. (2024). Incidental finding of leukaemia in circulating tumour DNA— the importance of a molecular tumour board. PubMed. 2(1). 12–12. 1 indexed citations
5.
Vroobel, Katherine, Ayoma D. Attygalle, Paula Proszek, et al.. (2024). Pole mutated endometrial carcinoma: Clinical and genomic characteristics from a real-world UK cohort.. Journal of Clinical Oncology. 42(16_suppl). e17600–e17600. 1 indexed citations
6.
Pascual, Javier, Miguel Martín, Paula Proszek, et al.. (2022). Baseline and longitudinal ctDNA biomarkers in GEICAM/2013-02 (PEARL) trial cohort 2 comparing palbociclib and fulvestrant (PAL + FUL) versus capecitabine (CAPE).. Journal of Clinical Oncology. 40(16_suppl). 1019–1019. 1 indexed citations
7.
8.
García-Murillas, Isaac, Paula Proszek, Charlotte Fribbens, et al.. (2018). Abstract P2-02-17: Circulating tumor DNA analysis with ultra-high sensitivity sequencing in metastatic breast cancer. Cancer Research. 78(4_Supplement). P2–2.
9.
10.
Lim, Joline S.J., Uzma Asghar, Nikolaos Diamantis, et al.. (2017). A phase I trial of selective PI3K inhibitor taselisib (tas) plus palbociclib (palb) with and without endocrine therapy incorporating pharmacodynamic (PD) studies in patients (pts) with advanced cancers.. Journal of Clinical Oncology. 35(15_suppl). 2573–2573. 2 indexed citations
11.
Litchfield, Kevin, Max Levy, Darshna Dudakia, et al.. (2016). Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility. Nature Communications. 7(1). 13840–13840. 29 indexed citations
12.
Pender, Alexandra, Sareena Rana, Elisa Izquierdo, et al.. (2016). 3 EGFR mutant circulating tumour DNA detection in advanced lung adenocarcinoma: optimising the application of a ctDNA diagnostic to real world clinical practice. Lung Cancer. 91. S2–S2. 1 indexed citations
13.
Kaiser, Martin, Eileen M. Boyle, Brian A. Walker, et al.. (2015). Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients. Blood. 126(23). 2983–2983.
14.
Pawlyn, Charlotte, Lorenzo Melchor, Alex Murison, et al.. (2014). Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood. 125(5). 831–840. 48 indexed citations
15.
Boyle, Eileen M., Paula Proszek, Martin Kaiser, et al.. (2014). A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma. Genes Chromosomes and Cancer. 54(2). 91–98. 17 indexed citations
16.
Pawlyn, Charlotte, Martin Kaiser, Brian A. Walker, et al.. (2014). The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact. Blood. 124(21). 2194–2194. 2 indexed citations
17.
Melchor, Lorenzo, Alexander Murison, Eileen M. Boyle, et al.. (2014). The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment. Blood. 124(21). 640–640. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sumito Shingaki Breakdown of academic impact, for papers by L. Qiu Breakdown of academic impact, for papers by Omar Saavedra Breakdown of academic impact, for papers by Sandra Salazar Breakdown of academic impact, for papers by Sivahari Prasad Gorantla Breakdown of academic impact, for papers by Yusuke Isshiki Breakdown of academic impact, for papers by Yih-Chih Chan Breakdown of academic impact, for papers by Gabriela Borsaru Breakdown of academic impact, for papers by Ikuko Omori Breakdown of academic impact, for papers by Max F. Levine
Rankless by CCL
2026